Cholesterol Med, Fenofibrate, Might Slow Vision Loss in People With Diabetes
25 Jun 2024
Drug ApprovalClinical Result
TUESDAY, June 25, 2024 -- A well-established cholesterol-lowering drug appears to significantly slow the progression of a diabetes-related eye disease, a new trial shows.
Fenofibrate (Tricor) has been approved since 2004 as a means of lowering cholesterol. Now, this new study shows that fenofibrate also can reduce the progression of diabetic retinopathy by 27% compared to placebo.
The findings were published June 21 in the journal NEJM Evidence and presented simultaneously at the American Diabetes Association’s annual meeting in Orlando, Fla.
“Diabetic retinopathy remains a leading cause of visual loss and we need simple strategies that can be widely used to reduce the progression of diabetic eye disease,” said researcher David Preiss, an associate professor at Oxford Population Health in the UK.
The results from the new trial “suggest that fenofibrate may provide a valuable addition to treat people with diabetic retinopathy,” Preiss added in a meeting news release.
Diabetic retinopathy occurs when elevated blood sugar levels damage blood vessels in the back of the eye. The vessels start to swell and leak, eventually leading to blurry vision, blank spots and blindness.
For this study, researchers recruited 1,151 adults in Scotland who had developed early diabetic retinopathy or macular degeneration. They were randomly assigned to take either fenofibrate tablets or a placebo.
Over four years, nearly 23% of people taking fenofibrate had their eye disease worsen, compared with 29% on a placebo, results show.
Fenofibrate also cut the risk of developing macular edema, which is a potentially harmful swelling in the retina.
Participants’ progress will continue to be tracked, to better understand the long-term effects of fenofibrate on health, researchers said.
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Drugs
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.